How is relapsed or refractory mantle cell lymphoma (MCL) treated?

Updated: Mar 15, 2019
  • Author: Muhammad Rashid Abbasi, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


The following regimens have been studied for relapsed or refractory MCL:

  • R-hyper-CVAD
  • Hyper-CVAD with or without rituximab followed by ASCT
  • Nucleoside analogues and combinations
  • Salvage chemotherapy combinations followed by ASCT
  • Bortezomib (Velcade)
  • Lenalidomide (Revlimid)
  • Ibrutinib (Imbruvica)
  • Radioimmunotherapy
  • Rituximab
  • Rituximab and thalidomide combination
  • Acalabrutinib (Calquence)
  • High-dose chemotherapy with autologous bone marrow or stem cell transplantation

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!